Claudia Zylberberg is the founder and CEO of Akron Biotechnology, a leading developer and manufacturer of cGMP-grade ancillary materials and a purveyor of specialized services critical to the clinical development and commercialization of advanced therapies. She has developed various patented and patent-pending technologies, including cryopreservation solutions, oligonucleotides, and recombinant protein formulations, and has authored numerous academic articles in high-impact publications. She holds advisory positions at the International Society for Cellular Therapy (ISCT), the International Society for Stem Cell Research (ISSCR), the Alliance for Regenerative Medicine (ARM) Foundation, and the National Academy of Science’s (NAS) Regenerative Medicine Forum, among others.
Dr. Zylberberg has engaged in several multi-stakeholder initiatives to formalize and strengthen the regenerative medicine industry through standardization, co-founding the Standards Coordinating Body (SCB) and driving standards development as part of the US Technical Advisory Group (TAG) to the International Organization for Standardization (ISO). Her extensive experience in cell and tissue banking, process development, and recombinant protein manufacturing has been instrumental for the development of new products critical to the advancement of the regenerative medicine industry.
Copyright FORM 2019
Designed by Ant Solutions